KRAS and colorectal carcinoma: K-Ras mutation plays a significant role in the prognosis of patients with advanced CRC and can affect the response to Cetuximab, a monoclonal antibody-based therapy that improves overall and progression-free survival in CRC patients who do not respond to chemotherapy [39].